Hatteras Venture Partners Closes Fund V, at over $150M

Durham, N.C.-based venture capital firm Hatteras Venture Partners closed its fifth fund with over $150m in total capital.

Hatteras Venture Partners V (HVP V) will continue the firm’s strategy of building biopharmaceutical, medical device, diagnostics, and health IT companies based upon technology from leading academic institutions such as UNC-Chapel Hill, Duke University, Emory, Georgia Tech, Johns Hopkins, Vanderbilt, Yale, Harvard, University of Michigan, and the University of Florida, by investing at the seed and early stage.

Led by Clay Thorp, General Partner, the firm will allocate a portion of HVP V to Hatteras Discovery to expand its model of company formation.

Portfolio companies with recent successes meeting clinical and/or financial milestones include G1 Therapeutics, Clearside Biomedical, GrayBug Vision, Viamet Pharmaceutials, Lysosomal Therapeutics, Orig3n, Clinipace, and GeneCentric.



Join the discussion